Mustang Bio (NASDAQ: MBIO) — Perfil da empresa, notícias e dados financeiros
Mustang Bio is a biopharmaceutical company focusing on innovative gene and cell therapies for hematologic cancers and rare diseases.
Mustang Bio
Mustang Bio (NASDAQ:MBIO) is a biopharmaceutical company focused on the development of innovative gene and cell therapies. This includes a wide range of treatments for hematologic cancers, solid tumors, and rare genetic diseases. The company's projects harness cutting-edge technology and groundbreaking research in CAR T therapies and gene therapies to address unmet medical needs. Mustang Bio aims to transform patient lives through scientific excellence and dynamic partnerships with leading academic institutions. Their objective is to advance these therapies from the laboratory to clinical trials and ultimately, to patients who need them the most, with a commitment to safety, efficacy, and accessibility.
Resumo
Operações
Produtos e/ou serviços de Mustang Bio
- MB-107 and MB-207, lentiviral gene therapies for X-linked Severe Combined Immunodeficiency (XSCID), showing promising treatment improvements.
- MB-106, a CD20-targeted, autologous CAR T therapy for B-cell Non-Hodgkin lymphomas and chronic lymphocytic leukemia, with positive trial outcomes.
- MB-102, a CD123-targeted CAR T cell therapy for acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and high-risk myelodysplastic syndrome, in early clinical trials.
- MB-104, a CAR T therapy for multiple myeloma and light chain amyloidosis, designed to target CS1 and BCMA, in preclinical development.
- MB-101, an IL13Ra2-targeted CAR T cell therapy for glioblastoma multiforme, demonstrating potential in early clinical evaluations.
- MB-108, an oncolytic virus therapy using C134, a herpes simplex virus, for glioblastoma, in early phase testing, showcasing a novel approach to solid tumors.
equipe executiva do Mustang Bio
- Michael S. WeissExecutive Chairman
- Manuel LitchmanPresident, CEO, Interim CFO & Director
- Peter CarneyController & Interim Chief Accounting Officer
- Greg FurrowChief Quality Officer
- Robyn M. HunterCorporate Secretary
Principais indicadores financeiros
Resultados divulgados pela Mustang Bio, em USD.
- Cap. de mercado
- 2,7 mi
- Receita (TTM)
- -50 mil
- P/L
- —
- LPA (diluído, TTM)
- -0.4
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -2,4 mi | -1,9 mi | |
| 0 | -16,2 mi | -15,8 mi | |
| 0 | -50,7 mi | -51,6 mi | |
| 0 | -76,2 mi | -77,5 mi |